Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents

The rapidly expanding knowledge regarding neoplastic diseases is providing a plethora of new targets for drug discovery and development as exemplified by recent data in renal cell carcinoma. The initial experience with molecularly "targeted" agents has demonstrated that development of the...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology reports 2005-03, Vol.7 (2), p.116-122
Main Authors: Desai, Apurva A, Stadler, Walter M
Format: Article
Language:English
Subjects:
Angiogenesis Inhibitors - pharmacology
Angiogenesis Inhibitors - therapeutic use
Antibodies, Monoclonal - pharmacology
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Benzenesulfonates - pharmacology
Benzenesulfonates - therapeutic use
Bevacizumab
Carcinoma, Renal Cell - drug therapy
Clinical Trials as Topic
Enzyme Inhibitors - therapeutic use
Humans
Indoles - pharmacology
Indoles - therapeutic use
Kidney Neoplasms - drug therapy
Niacinamide - analogs & derivatives
Phenylurea Compounds
Protein Kinase Inhibitors - therapeutic use
Pyridines - pharmacology
Pyridines - therapeutic use
Pyrroles - pharmacology
Pyrroles - therapeutic use
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Receptor, Epidermal Growth Factor - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The rapidly expanding knowledge regarding neoplastic diseases is providing a plethora of new targets for drug discovery and development as exemplified by recent data in renal cell carcinoma. The initial experience with molecularly "targeted" agents has demonstrated that development of the newer non-cytotoxic agents will provide unique challenges requiring modification of many traditional drug development concepts and methods. We discuss recently reported data from a few renal cell carcinoma trials with putative cytostatic agents and highlight issues that need to be addressed for efficient development of cytostatic agents during various phases of clinical development.
ISSN:1523-3790
1534-6269
DOI:10.1007/s11912-005-0037-6